Assay of active pharmaceutical ingredients in drug products based on relative response factors: Instrumentation insights and practical considerations

被引:0
|
作者
Liu, Lisa [1 ]
Mouallem, Ariel [1 ]
Xiao, Kang Ping [1 ]
Meisel, Jerry [1 ]
机构
[1] Bayer Consumer Hlth, Global R&D Prod Dev Ctr, Morristown, NJ 07960 USA
关键词
HPLC relative response factor (RRF); Potency assay; Slit width; Step width; Band width; 3D/2D data collection module; PERFORMANCE LIQUID-CHROMATOGRAPHY; REFERENCE-STANDARD; MULTI-COMPONENTS; ULTRAVIOLET; RUGGEDNESS; IMPURITIES;
D O I
暂无
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Relative Response Factors (RRFs) can be used for quantitation of one compound against another and it is widely used for Impurity analysis of pharmaceutical products; however, the application in potency assay is limited. Through an extensive study shown in this paper, it can be concluded that using the "RRF methodology" for potency assay is much more challenging compared to impurity analysis, due to the much tighter criteria required for potency analysis. The effects of instrument settings, which are rarely discussed or recognized in current HPLC analytical method development and quality release testing, are discussed. These factors impact the RRF just as much as other commonly recognized HPLC parameters. The effects of UV detector settings, i.e. Slit Width, Step Width, Band Width, and Data Collection Module, have been explored. This phenomenon has been demonstrated using three compounds to observe the impact of their quantitation due to the significant RRF variations. Finally, principles to reduce RRF variations have been discussed, and practical considerations of RRF application to method development and method transfer are provided. (C) 2020 The Authors. Published by Elsevier B.V.
引用
收藏
页数:13
相关论文
共 28 条
  • [21] Hypoxic Incubation Conditions for Optimized Manufacture of Tenocyte-Based Active Pharmaceutical Ingredients of Homologous Standardized Transplant Products in Tendon Regenerative Medicine
    Jeannerat, Annick
    Peneveyre, Cedric
    Armand, Florence
    Chiappe, Diego
    Hamelin, Romain
    Scaletta, Corinne
    Hirt-Burri, Nathalie
    Roessingh, Anthony de Buys
    Raffoul, Wassim
    Applegate, Lee Ann
    Laurent, Alexis
    CELLS, 2021, 10 (11)
  • [22] The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development
    Dobo, KL
    Greene, N
    Cyr, MO
    Caron, S
    Ku, WW
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 44 (03) : 282 - 293
  • [23] Evaluation of "Toolkit" consisting of handheld and portable analytical devices for detecting active pharmaceutical ingredients in drug products collected during a simultaneous nation-wide mail blitz
    Lanzarotta, Adam
    Kern, Sara
    Batson, JaCinta
    Falconer, Travis M.
    Fulcher, Moseley
    Gaston, Kirk W.
    Kimani, Martin M.
    Lorenz, Lisa
    Morales-Garcia, Flavia
    Ranieri, Nicola
    Skelton, David
    Thatcher, Michael D.
    Toomey, Valerie M.
    Voelker, Sarah
    Witkowski, Mark R.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 203
  • [24] Implementation of the 14th Amendment of the German drug law and the decree for the production of medicinal products and active pharmaceutical ingredients in transfusion medicine facilities - The of view of a federal state authority
    Siegel, Wiebke
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2007, 34 (02) : 115 - 119
  • [25] Recent Trends in Product Development and Regulatory Issues on Impurities in Active Pharmaceutical Ingredient (API) and Drug Products. Part 1: Predicting Degradation Related Impurities and Impurity Considerations for Pharmaceutical Dosage Forms
    Alsante, Karen M.
    Huynh-Ba, Kim
    Baertschi, Steven W.
    Reed, Robert A.
    Landis, Margaret S.
    Kleinman, Mark H.
    Foti, Christopher
    Rao, Venkatramana M.
    Meers, Paul
    Abend, Andreas
    Reynolds, Daniel W.
    Joshi, Biren K.
    AAPS PHARMSCITECH, 2014, 15 (01): : 198 - 212
  • [26] Recent Trends in Product Development and Regulatory Issues on Impurities in Active Pharmaceutical Ingredient (API) and Drug Products. Part 1: Predicting Degradation Related Impurities and Impurity Considerations for Pharmaceutical Dosage Forms
    Karen M. Alsante
    Kim Huynh-Ba
    Steven W. Baertschi
    Robert A. Reed
    Margaret S. Landis
    Mark H. Kleinman
    Christopher Foti
    Venkatramana M. Rao
    Paul Meers
    Andreas Abend
    Daniel W. Reynolds
    Biren K. Joshi
    AAPS PharmSciTech, 2014, 15 : 198 - 212
  • [27] Rapid detection of active pharmaceutical ingredients in drug products collected at an international mail facility by a satellite laboratory using a ?toolkit? consisting of a handheld Raman spectrometer, portable mass spectrometer and portable FT-IR spectrometer
    Lanzarotta, Adam
    Kern, Sara
    Batson, JaCinta
    Boyd, Brian
    Kimani, Martin M.
    Kuo, Weiwei
    LaGarde, Donna
    Loh, Mark
    Adeoshun, Laurenee L.
    Lorenz, Lisa
    Melendez, Rebeca
    Morales-Garcia, Flavia
    Thatcher, Michael
    Wetherby Jr, Anthony E.
    Witkowski, Mark R.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 224
  • [28] Integration of a plasma protein binding factor to the Chemical-Specific Adjustment Factor (CSAF) for facilitating the estimation of uncertainties in interspecies extrapolations when deriving health-based exposure limits for active pharmaceutical ingredients: Investigation of recent drug datasets
    Poulin, Patrick
    Arnett, Richard
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2017, 91 : 142 - 150